Sadarangani, M;
Sell, T;
Iro, MA;
Snape, MD;
Voysey, M;
Finn, A;
Heath, PT;
Bona, G;
Esposito, S;
Diez-Domingo, J;
et al.
Sadarangani, M; Sell, T; Iro, MA; Snape, MD; Voysey, M; Finn, A; Heath, PT; Bona, G; Esposito, S; Diez-Domingo, J; Prymula, R; Odueyungbo, A; Toneatto, D; Pollard, AJ; European MenB Vaccine Study Group
(2017)
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.
CMAJ, 189 (41).
E1276-E1285.
ISSN 1488-2329
https://doi.org/10.1503/cmaj.161288
SGUL Authors: Heath, Paul Trafford
![]() |
Microsoft Word (.docx)
Accepted Version
Available under License ["licenses_description_publisher" not defined]. Download (750kB) |
Abstract
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12-24 months of age received a booster at 4 years of age. Vaccine-naive age-matched toddlers received 2 doses of 4CMenB. Human serum bactericidal antibody titres against reference strains H44/76, 5/99, NZ98/254 and M10713 were evaluated before and after innoculation with 4CMenB vaccine in 4-year-old children. RESULTS: Of 332 children in the study, 123 had previously received 4CMenB and 209 were vaccine-naive controls. Before the booster, the proportions of participants (previously vaccinated groups compared with controls) with hSBA titres of 1:5 or more were as follows: 9%-11% v. 1% (H44/76), 84%-100% v. 4% (5/99), 0%-18% v. 0% (NZ98/254) and 59%-60% v. 60% (M10713). After 1 dose of 4CMenB in previously immunized children, the proportions of participants achieving hSBA titres of 1:5 or more were 100% (H44/76 and 5/99), 70%-100% (NZ98/254) and 90%-100% (M10713). INTERPRETATION: We found that waning of hSBA titres by 4 years of age occurred after 2 doses of 4CMenB vaccine administered at 12-24 months, and doses at 12-24 months have a priming effect on the immune system. A booster may be necessary to maintain hSBA titres of 1:5 or more among those children with increased disease risk. Trial registration: ClinicalTrials.gov, no. NCT01717638.
Item Type: | Article | ||||||
---|---|---|---|---|---|---|---|
Additional Information: | © 2017 Joule Inc. or its licensors | ||||||
Keywords: | General & Internal Medicine, 11 Medical And Health Sciences | ||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||
Journal or Publication Title: | CMAJ | ||||||
ISSN: | 1488-2329 | ||||||
Language: | eng | ||||||
Dates: |
|
||||||
Publisher License: | Publisher's own licence | ||||||
PubMed ID: | 29038320 | ||||||
Web of Science ID: | WOS:000413572900003 | ||||||
Go to PubMed abstract | |||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/108723 | ||||||
Publisher's version: | https://doi.org/10.1503/cmaj.161288 |
Statistics
Actions (login required)
![]() |
Edit Item |